Prior to joining Senda, Stu served as Vice President of Platform Biology at Korro Bio where he built and led High Throughput Screening and Platform Biology functions and served on the leadership team. In his time at Korro, he helped to establish their ADAR-mediated RNA editing platform and transitioned the company from seed funding through Series B.
Previously, at Alnylam Pharmaceuticals, Stu established and led the RNAi Lead Development group, which was responsible for the lead development and optimization for all clinical candidates in the Alnylam pipeline. He contributed to the discover and optimization of multiple products including Onpattro, the first ever approved RNAi therapeutic; Givlarri, the first approved siRNA conjugate; and several other approved products for orphan and large indignations. He also initiated work on delivery of siRNAs to the central nervous system, co-led the CNS delivery platform and made significant contributions across Alnylam’s platform including optimization of siRNA design for GalNAc conjugates.
Stu trained as a research fellow in the department of Genetics at Harvard Medical School and Dana-Farber Cancer Institute, where he focused on genomics and proteomics. He received his Ph.D. through the genetics program at Cold Spring Harbor Laboratory and Stony Brook University studying the genetics of apoptosis.